Abstracts Archive - Page 333 of 1683 - ATC Abstracts

2020 American Transplant Congress
Cardiovascular Risk Factors in Patients after Liver Transplantion
M. Adamczak¹, D. Gojowy¹, J. Stompor¹, J. Adamusik¹, G. Smiech¹, H. Karkoszka¹, R. Krol², A. Wiecek¹
¹Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland, ²Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland
*Purpose: The aim of this study was to estimate the prevalence of selected cardiovascular risk factors in patients after liver transplantation (LTx).*Methods: Medical records from…
2020 American Transplant Congress
Practice Patterns and Provider Adherence to Long Term Management Guidelines in the Post Liver Transplant (LT) Patient
F. Pradhan¹, P. Kang², A. Seetharam¹, S. Mehta¹, R. Nathan¹, M. Fallon¹, N. Patel¹
¹Department of Gastroenterology and Hepatology, Banner University Medical Center, Phoenix, AZ, ²Department of Epidemiology and Biostatistics, University of Arizona, Phoenix, AZ
*Purpose: Long-term use of immunosuppression is associated with increased risks of cardiovascular disease, chronic kidney disease, and cancer. We assessed practice patterns and provider adherence…
2020 American Transplant Congress
Incidence of Rejection One Year after Liver Transplantation Associated with Early versus Late Steroid Withdrawal
S. Yun, L. Miko, J. Ahmad
The Mount Sinai Hospital, New York, NY
*Purpose: The adverse effects associated with steroid use make earlier steroid withdrawal desirable, but the optimal time for withdrawal after liver transplantation (LT) is not…
2020 American Transplant Congress
Stanford Integrated Psychosocial Assessment for Transplant Predicts Immunosuppression Non-Adherence after Liver Transplantation
S. Deutsch-Link¹, E. Weinberg², M. McDougal³, L. Jones⁴, T. Bitterman², M. Serper²
¹Medicine, University of Pennsylvania, Philadelphia, PA, ²Gastroenterology & Hepatology, University of Pennsylvania, Philadelphia, PA, ³Drexel University, Philadelphia, PA, ⁴PCOM, Philadelphia, PA
*Purpose: Patients with end-stage liver disease presenting for liver transplant (LT) evaluation have a high burden of psychosocial comorbidities. The Stanford Integrated Psychosocial Assessment for…
2020 American Transplant Congress
Early Allograft Dysfunction as a Predictor for Graft and Patient Survival after Liver Transplantation
L. I. Mazilescu, N. Selzner, G. Sapisochin, T. Reichman, M. Bhat, M. Cattral, L. Lilly, I. McGilvray, Z. Galvin, A. Ghanekar, M. Selzner
Multi Organ Transplant Program, Toronto General Hospital, Toronto, ON, Canada
*Purpose: Early allograft dysfunction (EAD) after liver transplantation has been associated with long-term reduced graft and patient survival. In this single center cohort study, we…
2020 American Transplant Congress
The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma
K. Sasaki¹, J. McVey¹, D. Firl², Y. Inaba³, C. D. Kwon¹, K. Hashimoto¹, F. Aucejo¹
¹The Cleveland Clinic, Cleveland, OH, ²Duke University, Durham, NC, ³Chiba University, Chiba, Japan
*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…
2020 American Transplant Congress
Risk Factors for Hepatic Artery Thrombosis: A Single Center Study with Multiple Surgeons
M. Fitzsimons¹, M. Bindal², J. Buggs³, D. Patino⁴, E. Rogers³, A. Kumar¹, A. Lu³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴University of Tampa, Tampa, FL
*Purpose: Hepatic Artery Thrombosis (HAT) is an uncommon complication after liver transplant, but its occurrence can lead to significant and fatal outcomes. Our objective was…
2020 American Transplant Congress
Differences in Immunosuppressive Therapy among Liver Retransplantation Recipients in a National Cohort
A. K. Mezochow, P. L. Abt, T. Bittermann
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT). This study explored: (i) factors associated with induction…
2020 American Transplant Congress
Impact of the Baseline Anti-A/B IgG Titer on the Clinical Outcome in ABO-Incompatible Liver Transplantation
J. Lee¹, E. Kim¹, S. Yang¹, D. Kim², M. Ju³, J. Lee¹, M. Kim¹, S. Kim¹, D. Joo¹
¹Department of Transplantation Surgery, Severance Hospital, Seoul, Korea, Republic of, ²Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, ³Department of Surgery, Gangam Severance Hospital, Seoul, Korea, Republic of
*Purpose: The use of ABO incompatible (ABOi) living donors is an attractive solution for expanding the liver donor pool. We investigated the impact of the…
2020 American Transplant Congress
Risk Factors Associated with Hepatic Artery Thrombosis in the Modern Era
M. Krach, A. Kernodle, P. Chiang, D. Segev, A. Massie, J. Garonzik-Wang
Johns Hopkins, Baltimore, MD
*Purpose: Historically, hepatic artery thrombosis (HAT) has been associated with certain risk factors, such as donor age, cold ischemia time, and split grafts; it is unclear…